SCHEMBL475525

SCHEMBL475525

COCCN1CCN(C[C]=O)CC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 2/20 0.41
KDM1A O60341 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
ALDH1A1 P00352 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
GBA1 P04062 1/20 0.33
NAMPT P43490 1/20 0.32
MAP4K4 O95819 1/20 0.32
DRD3 P35462 3/20 0.32
SLC29A1 Q99808 1/20 0.32
KDM2B Q8NHM5 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
NPC1 O15118 1/20 0.31
DRD2 P14416 1/20 0.30
PIK3CA P42336 1/20 0.30
MTOR P42345 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4893194 0.82 HSD11B1 (0.47) HSD11B1KDM1ATDP1ALDH1A1KDM4E
SCHEMBL6057032 0.82
SCHEMBL8149011 0.82 HSD11B1 (0.47) HSD11B1KDM1ATDP1ALDH1A1KDM4E
SCHEMBL1308858 0.79 ALDH1A1 (0.43) HSD11B1KDM1AALDH1A1MEN1KMT2A
SCHEMBL1783124 0.79 HSD11B1 (0.41) HSD11B1KDM1ATDP1ALDH1A1KDM4E
SCHEMBL8424491 0.76
SCHEMBL14940714 0.76 DRD2 (0.39) MEN1KMT2ADRD3LMNADRD2
SCHEMBL3318840 0.76 HSD11B1 (0.45) HSD11B1KDM1ATDP1ALDH1A1KDM4E
SCHEMBL475176 0.75 NPSR1 (0.41) TDP1ALDH1A1KDM4ELMNA
SCHEMBL84800 0.75 HSD11B1 (0.43) HSD11B1ALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2412706-B1 NOVEL HYDROXAMATE DERIVATIVE, A PRODUCTION METHOD FOR THE SAME, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARM CORP (KR) 2014-10-29 EP disclosed
US-8466161-B2 Hydroxamate derivative, a production method for the same, and a pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2013-06-18 US disclosed
US-20120028963-A1 NOVEL HYDROXAMATE DERIVATIVE, A PRODUCTION METHOD FOR THE SAME, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2012-02-02 US disclosed
EP-2412706-A2 NOVEL HYDROXAMATE DERIVATIVE, A PRODUCTION METHOD FOR THE SAME, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2012-02-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028963-A1 NOVEL HYDROXAMATE DERIVATIVE, A PRODUCTION METHOD FOR THE SAME, AND A PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HAAO, HPD, HCAR2 HSD11B1 243/4885KDM1A 732/4885TDP1 2929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.